wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1252.
1 2 3 4 5 ... 26 Next »

Medicine/Pharmacology - Physics/Materials Science
20.10.2017
EPFL spin-off Abionic poised to break into the US market
EPFL spin-off Abionic poised to break into the US market
The United States Food and Drug Administration has just registered Abionic's rapid allergy diagnostic system, which tests for sensitivity to four common respiratory allergens in the United States.
Medicine/Pharmacology
18.10.2017
Novartis drug Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Nearly 70% of patients maintained platelet counts of >=30×10 9 /L without rescue therapy for prolonged periods, reducing the overall risk of bleeding   More than one-third of patients permanently
Medicine/Pharmacology - Life Sciences
16.10.2017
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to
Medicine/Pharmacology - Administration/Government
10.10.2017
Physics/Materials Science - Medicine/Pharmacology
09.10.2017
Sticking instead of stitching
In spite of medical advances, wound-related complications arising after operations can still be life-threatening. In order to avoid these complications in the future, a new nanoparticle-based tissue glue has been developed by researchers at Empa. There are internal and external areas of the body where it is difficult to apply stitches.
Medicine/Pharmacology - Administration/Government
06.10.2017
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses
Medicine/Pharmacology - Microtechnics/Electroengineering
06.10.2017
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon IOL
AutonoMe(TM) preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion during cataract surgery   New Clareon IOL in vitro data and early clinical experience to be prese
Medicine/Pharmacology - Computer Science/Telecom
05.10.2017
CrowdAI: the open, data-science challenge platform
CrowdAI: the open, data-science challenge platform
crowdAI, an EPFL-developed open data science challenge platform that hosts machine learning competitions, has been awarded over $100,000 from Amazon and Nvidia for its latest challenge, "Learning to Run" .
Medicine/Pharmacology
03.10.2017
An Animated Cartoon against Parasitic Worm Infections
An Animated Cartoon against Parasitic Worm Infections
The educational animation film 'Koko et les lunettes magiques' aims to strengthen the awareness of school-aged children and their families in Côte d'Ivoire against parasitic worm infections by showing them simple, but effective preventive hygiene practices. The animation film is the key element in an intervention study in western Côte d'Ivoire conducted by Swiss TPH, the Centre Suisse des Recherches Scientifiques en Côte d'Ivoire and the Université Félix Houphouët-Boigny, Côte d'Ivoire.
Life Sciences - Medicine/Pharmacology
03.10.2017
Clumps as temporary storage
Clumps as temporary storage
Researchers at ETH have discovered that the formation of protein aggregates in yeast cells is reversible. This casts new light on human diseases that can be attributed to certain protein aggregates. Protein aggregates have a bad reputation. A number of human diseases, especially those of the nervous system, such as Alzheimer's, Parkinson's, or amyotrophic lateral sclerosis (ALS), are due to the clumping of degenerate proteins in nerve cells, creating aggregates that the cells cannot dissolve.
Medicine/Pharmacology
03.10.2017
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams The NAVIFY Tumor Board solution is a new, cloud-based software solution that fundamentally changes the wa
Medicine/Pharmacology - Physics/Materials Science
02.10.2017
Biosensor for heavy metals
Biosensor for heavy metals
A team of Empa scientists has developed a biosensor which allows them to detect elevated concentrations of copper in a simple, quick and economic way. Copper, like other heavy metals is problematic in high concentrations, both for the environment and for human health. It is no secret that heavy metals such as copper are dangerous substances which can have grave consequences for both our environment and for human health.
Medicine/Pharmacology
02.10.2017
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
Clareon intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations   Congress program highlights Alcon's 70-year legacy of innov
Medicine/Pharmacology - Life Sciences
28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch
Chemistry - Medicine/Pharmacology
28.09.2017
Biodegradable microsensors for food monitoring
Biodegradable microsensors for food monitoring
A new generation of microsensors could provide the vital link between food products and the Internet of Things. ETH researchers have developed an ultra-thin temperature sensor that is both biocompatible and biodegradable. Nowadays microsensors are already used in many different applications, such as the detection of poisonous gases.
Medicine/Pharmacology
26.09.2017
Reduced Efficacy of Anthelmintic Drugs
Approximately 1.5 billion people worldwide are affected by soil-transmitted helminth infections. Efficacy of current treatments is decreasing, as indicated in a systematic review and network meta-analysis by the Swiss Tropical and Public Health Institute, published in the British Medical Journal (BMJ).
Medicine/Pharmacology
26.09.2017
Even Open-Label Placebos Work - if They Are Explained
Even Open-Label Placebos Work - if They Are Explained
For some medical complaints, open-label placebos work just as well as deceptive ones. As psychologists from the University of Basel and Harvard Medical School report in the journal Pain, the accompanying rationale plays an important role when administering a placebo. The successful treatment of certain physical and psychological complaints can be explained to a significant extent by the placebo effect.
Life Sciences - Medicine/Pharmacology
25.09.2017
New regulator for liver regeneration
New regulator for liver regeneration
By performing large-scale proteomics analysis of liver proteins, ETH researchers have discovered a protein that is essential for liver regeneration. They have also figured out the mechanism of the protein's function. The liver is a wonderful thing: it's the only organ able to fully regenerate with no scar tissue formation, even after major injury.
Medicine/Pharmacology
22.09.2017
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people wit
Medicine/Pharmacology - Life Sciences
22.09.2017
Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA study Roche announced today that the European Commission (EC) has approved Actemra /RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.
Medicine/Pharmacology - Physics/Materials Science
22.09.2017
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche announced today that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.
Medicine/Pharmacology - Administration/Government
22.09.2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model   GIPAP was introduced 15 years ago and has provi
Medicine/Pharmacology - Life Sciences
20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv
Medicine/Pharmacology
18.09.2017
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche announced today that the phase III MURANO study, which evaluated Venclexta /Venclyxto (venetocla
Medicine/Pharmacology - Life Sciences
16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled   Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair   Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l
Medicine/Pharmacology - Environment/Sustainable Development
15.09.2017
The University of Bern on the move
Media releases, information for representatives of the media Media Relations (E) Research at the University of Bern is being intensified: Innovative joint projects from different subject areas are being supported with the new Interfaculty Research Cooperations IRC.
Medicine/Pharmacology
15.09.2017
Life Expectancy Increases in Switzerland
Life Expectancy Increases in Switzerland
Countries have saved more lives over the past decade according to the annual Global Burden of Diseases (GBD) study published yesterday. In Switzerland, life expectancy has increased to 85 years for women and to 81 years for men. The Swiss Tropical and Public Health Institute contributed to the GDB, the world's largest scientific collaboration on population health.
Medicine/Pharmacology - Psychology
15.09.2017
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear. A meta-analysis of data from over 6,500 patients has now shown that, although antidepressants are more effective than placebos, the difference is minor and varies according to the type of mental disorder.
Medicine/Pharmacology
14.09.2017
Parasitic Worms in Siberia
Parasitic Worms in Siberia
Millions of people worldwide are infected with parasitic worms, most of them in tropical low-income settings.
Medicine/Pharmacology - Life Sciences
14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.
Medicine/Pharmacology - Life Sciences
14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem
Medicine/Pharmacology - Life Sciences
13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.
Medicine/Pharmacology
13.09.2017
Novartis’ Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx (secukinumab) is the first and only fully human IL-17A   inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis   Landmark data show that PASI 90 and PASI 100
Medicine/Pharmacology - Life Sciences
12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our
Medicine/Pharmacology
11.09.2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.
Medicine/Pharmacology - Media
11.09.2017
Adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relapse
Medicine/Pharmacology - Life Sciences
09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD   Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).
Medicine/Pharmacology - Earth Sciences
08.09.2017
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with previous lampalizumab trials and other intravitreal therapies Results from the second phase III study, Chro
Medicine/Pharmacology - Life Sciences
08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.
Medicine/Pharmacology - Life Sciences
07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten
Medicine/Pharmacology - Life Sciences
06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Tuberculosis Research Against "Super Resistant Bacteria"
To fall ill from tuberculosis remains a great danger. A research team led by cell biologist Sébastien Gagneux at the Swiss Tropical and Public Health Institute (Swiss TPH) examines the antibiotic resistance mechanisms of Mycobacterium tuberculosis.
Medicine/Pharmacology
05.09.2017
Medicine/Pharmacology - Life Sciences
05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a   There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies   Children and adolescents living with MS face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to school     PARADIGMS is a first of its kind study in pediatric MS.
Medicine/Pharmacology - Business/Economics
04.09.2017
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position.
Medicine/Pharmacology - Business/Economics
31.08.2017
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO Presidential Symposium New data from phase III ALEX and ALUR studies provide additional evidence supporting the use o
Environment/Sustainable Development - Medicine/Pharmacology
31.08.2017
1 2 3 4 5 ... 26 Next »

 
 
Jobs listed on